Christine Zedelmayer Sells 86,012 Shares of Equillium (NASDAQ:EQ) Stock

Equillium, Inc. (NASDAQ:EQ) COO Christine Zedelmayer sold 86,012 shares of the stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $2.80, for a total value of $240,833.60. Following the sale, the chief operating officer owned 62,586 shares in the company, valued at $175,240.80. The trade was a 57.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Zedelmayer also recently made the following trade(s):

• On Wednesday, May 27th, Christine Zedelmayer sold 9,821 shares of Equillium stock. The stock was sold at an average price of $2.70, for a total value of $26,516.70.
• On Friday, March 13th, Christine Zedelmayer sold 120,312 shares of Equillium stock. The stock was sold at an average price of $2.50, for a total value of $300,780.00.
• On Monday, March 9th, Christine Zedelmayer sold 181,219 shares of Equillium stock. The stock was sold at an average price of $2.00, for a total transaction of $362,438.00.

Equillium Price Performance

Shares of EQ stock traded up $0.06 during trading hours on Friday, reaching $2.90. The stock had a trading volume of 853,917 shares, compared to its average volume of 480,896. The firm has a market capitalization of $183.37 million, a PE ratio of -9.06 and a beta of 1.67. The firm has a 50-day simple moving average of $2.09 and a 200-day simple moving average of $1.63. Equillium, Inc. has a twelve month low of $0.27 and a twelve month high of $3.10.

Equillium (NASDAQ:EQ) last posted its earnings results on Wednesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). On average, equities analysts anticipate that Equillium, Inc. will post -0.24 earnings per share for the current year.

More Equillium News

Here are the key news stories impacting Equillium this week:

• Positive Sentiment: Leerink Partners upgraded Equillium from market perform to outperform and lifted its price target to $6.00, suggesting meaningful upside from current levels. Leerink Upgrades Equillium (EQ) to Outperform
• Positive Sentiment: Roth Mkm reiterated a buy rating and set a $12.00 target, reinforcing a bullish view on Equillium’s pipeline and valuation. Equillium Receives Buy Rating from Roth Mkm
• Positive Sentiment: Equillium announced it will participate in the 2026 Jefferies Global Healthcare Conference, which could provide a catalyst if management shares favorable clinical or strategic updates. Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
• Positive Sentiment: Shareholders approved a reverse split and capital changes at the annual meeting, a step that can help maintain Nasdaq compliance and potentially improve the company’s capital structure. Equillium Shareholders Approve Reverse Split and Capital Changes
• Neutral Sentiment: Short interest was reported at 0 shares, indicating no meaningful bearish positioning in the latest update, though the figure appears unusual and may not be a reliable market signal. Short interest update
• Negative Sentiment: COO Christine Zedelmayer sold a combined 95,833 shares over two transactions, and insider Penny Tom sold 65,000 shares; although both were made under pre-arranged 10b5-1 plans, insider selling can still pressure sentiment. SEC Form 4 insider sales filing

Analyst Ratings Changes

Several analysts recently commented on the company. Roth Mkm restated a “buy” rating and issued a $12.00 target price on shares of Equillium in a research report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Equillium in a research report on Friday, March 27th. Cantor Fitzgerald assumed coverage on Equillium in a research note on Tuesday, April 7th. They issued an “overweight” rating and a $10.00 price target for the company. Stifel Nicolaus set a $5.00 price target on Equillium in a report on Thursday. Finally, Oppenheimer started coverage on shares of Equillium in a research note on Thursday, April 23rd. They set an “outperform” rating and a $7.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $7.57.

Institutional Investors Weigh In On Equillium

Several institutional investors have recently bought and sold shares of EQ. Dimensional Fund Advisors LP acquired a new stake in Equillium in the first quarter worth about $31,000. Virtu Financial LLC lifted its holdings in Equillium by 133.4% in the third quarter. Virtu Financial LLC now owns 23,779 shares of the company’s stock worth $34,000 after purchasing an additional 13,591 shares during the period. Millennium Management LLC bought a new position in Equillium during the 3rd quarter valued at $35,000. Persistent Asset Partners Ltd bought a new position in Equillium during the 3rd quarter valued at $99,000. Finally, OMERS ADMINISTRATION Corp bought a new position in Equillium during the 1st quarter valued at $100,000. Institutional investors and hedge funds own 27.05% of the company’s stock.

About Equillium

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.